Search
Jazz Pharmaceuticals PLC
JAZZAdd to Watchlist
240.830USD
-5.040-2.05%
Close 09-15 16:00（ET）
15.61BMarket Cap
584.08P/E TTM
More Details of Jazz Pharmaceuticals PLC Company
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Jazz Pharmaceuticals PLC Profile
Ticker SymbolJAZZ
Company nameJazz Pharmaceuticals PLC
IPO dateJan 18, 2012
CEOGala (Renee D)
Number of employees2800
Security typeOrdinary Share
Fiscal year-endJan 18
AddressFifth Floor, Waterloo Exchange
CityDUBLIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIreland
Postal code- -
Phone35316347800
Websitehttps://www.jazzpharma.com/
Ticker SymbolJAZZ
IPO dateJan 18, 2012
CEOGala (Renee D)
Company Executives of Jazz Pharmaceuticals PLC
Name
Name/Position
Position
Shareholding
Change
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.29M
+0.12%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Executive Chairman of the Board
Executive Chairman of the Board
316.19K
-1.90%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
49.08K
-8.08%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
26.00K
-74.69%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
24.89K
-13.43%
Ms. Mary Elizabeth (Liz) Henderson
Ms. Mary Elizabeth (Liz) Henderson
Senior Vice President - Technical Operations
Senior Vice President - Technical Operations
23.82K
-5.99%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
20.75K
-18.69%
Ms. Samantha Pearce
Ms. Samantha Pearce
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
19.48K
-4.00%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Director
Independent Director
17.55K
-0.58%
Ms. Anne O'Riordan
Ms. Anne O'Riordan
Independent Director
Independent Director
16.50K
+21.25%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.29M
+0.12%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Executive Chairman of the Board
Executive Chairman of the Board
316.19K
-1.90%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
49.08K
-8.08%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
26.00K
-74.69%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
24.89K
-13.43%
Ms. Mary Elizabeth (Liz) Henderson
Ms. Mary Elizabeth (Liz) Henderson
Senior Vice President - Technical Operations
Senior Vice President - Technical Operations
23.82K
-5.99%
FAQs
Who are the top five shareholders of Jazz Pharmaceuticals PLC?
The top five shareholders of Jazz Pharmaceuticals PLC are: Mr. Seamus C. Mulligan
How many institutions hold shares of Jazz Pharmaceuticals PLC (JAZZ)?
As of 2026Q1, 1229 institutions hold shares of Jazz Pharmaceuticals PLC, with a combined market value of approximately 70.31M, accounting for 112.06% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -754072.00.
What is the biggest source of revenue for Jazz Pharmaceuticals PLC?
In 2026Q1, the Xywav business generated the highest revenue for Jazz Pharmaceuticals PLC, amounting to 471.20M and accounting for 39.00% of total revenue.